A critical analysis and review of Lancet COVID-19 hydroxychloroquine study

References

• Qiu T, Liang S, Dabbous M, et al. Chinese guidelines related to novel coronavirus pneumonia. Preprints. 2020;2020040207.
   Google Scholar
• Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J, Parola P, et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. Mediterranee Infection. Pre-print., 2020.
   Google Scholar
• Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020. 03.22.20040758
   Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–2418.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. Jama, 2020.
   Google Scholar
• Mehra MR, Desai SS, Ruschitzka F, et al., Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet, 2020.
   Google Scholar
• Roche V Après l’OMS hier soir, l’ANSM annonce à son tour suspendre par précaution les essais cliniques évaluant l’hydroxychloroquine dans la prise en charge des patients atteints de Covid-19. [2020 May 30]. Available from: https://destinationsante.com/lansm-suspend-a-son-tour-les-essais-sur-la-chloroquine.html.
   Google Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. 2020 [cited 2020 May 30]. Available from: https://www.covid19treatmentguidelines.nih.gov/.
   Google Scholar
• Wang K, Zuo P, Liu Y, et al., Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clinical Infectious Diseases, 2020.
   Google Scholar
• Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Choueiri KT, Shah DP, et al., Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, 2020.
   Google Scholar
• Lee LYW, Cazier JB, Starkey T, et al., COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet.
   Google Scholar
• Funck-Brentano C, Salem J-E, Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? The Lancet.
   Google Scholar
• White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7(8):549–8.
   PubMed Web of Science ®Google Scholar
• Frommeyer G, Fischer C, Ellermann C, et al. Additive proarrhythmic effect of combined treatment with QT-prolonging agents. Cardiovasc Toxicol. 2018;18(1):84–90.
   Web of Science ®Google Scholar
• Little S Study finds lower COVID-19 death rate in metro vancouver ICUs than other cities. 2020. [2020 may 30]. Available from: https://globalnews.ca/news/6995240/study-lower-coronavirus-death-rate-vancouver-icus/.
   Google Scholar
• Singh AK, Singh R. Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19? Diabetes Metab Syndr. 2020;14(5):725–727.
   PubMed Web of Science ®Google Scholar
• Xu PP, Tian RH, Luo S, et al. Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics. 2020;10(14):6372–6383.
   PubMed Web of Science ®Google Scholar
• Hajifathalian K, Kumar S, Newberry C, et al. Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York city. Obesity(Silver Spring). 2020.
   Google Scholar
• Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15(5):e0233147.
   PubMed Web of Science ®Google Scholar
• Third of UK Covid-19 patients taken to hospital die, study finds 2020. [2020 May 29]. Available from: https://www.theguardian.com/uk-news/2020/apr/29/study-finds-a-third-of-uk-covid-19-patients-taken-to-hospital-are-dying.
   Google Scholar
• Santorelli G, Sheldon T, West J, et al. COVID-19 in-patient hospital mortality by ethnicity. Wellcome Open Res. 2020.
   Google Scholar
• Deshayes B Covid-19 en France: les statistiques du mercredi 3 juin 2020. 2020 [cited 2020 May 29]; Available from: https://www.linternaute.com/actualite/guide-vie-quotidienne/2489651-covid-19-en-france-les-statistiques-du-mercredi-3-juin-2020/.
   Google Scholar
• COVID-19 death rate at Metro Vancouver hospital ICUs notably lower than in other countries: study. 2020. [2020 May 30]. Available from: https://www.cbc.ca/news/canada/british-columbia/covid-19-coronavirus-metro-vancouver-hospital-icu-death-rate-1.5589695.
   Google Scholar
• Kunzmann K WHO suspends hydroxychloroquine treatment in COVID-19 solidarity trial. 2020. [2020 May 26]. Available from: https://www.contagionlive.com/news/who-hydroxychloroquine-treatment-covid-19-solidarity-trial.
   Google Scholar
• Yasgur BS More evidence hydroxychloroquine is ineffective, harmful in COVID-19. 2020. [2020 May 29]. Available from: https://www.mdedge.com/cardiology/article/222758/arrhythmias-ep/more-evidence-hydroxychloroquine-ineffective-harmful-covid.
   Google Scholar
• No improvement in death rate for COVID-19 patients who received hydroxychloroquine. 2020. [2020 May 26]. Available from: https://neurosciencenews.com/hcq-coronavirus-death-16449/.
   Google Scholar
• No evidence of benefit for chloroquine and hydroxychloroquine in COVID-19 patients, study finds. 2020. [2020 May 26]. Available from: https://www.sciencedaily.com/releases/2020/05/200522113712.htm.
   Google Scholar
• Sandercock P RECOVERY trialDMC chairman’s report. 2020. [2020 May 26]. Available from: https://www.recoverytrial.net/files/professional-downloads/2020_05_24-recovery-dmc-letter_.pdf.
   Google Scholar
• Horby P, Landray M. Recruitment to the RECOVERY trial (including the Hydroxychloroquine arm) REMAINS OPEN. 2020. [2020 May 26]. Available from: https://www.recoverytrial.net/files/professional-downloads/recovery_noticetoinvestigators_2020-05-24_1422.pdf.
   Google Scholar
• Watson J, An open letter to Mehra et al and The Lancet. Zenodo, 2020.
   Google Scholar
• Statement on data sharing in public health emergencies. 2016. [2020 May 26]. Available from: https://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies.
   Google Scholar
• Risch HA. Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped-up immediately as key to the pandemic crisis. Am J Epidemiol. 2020.
   Web of Science ®Google Scholar
• Raoult D Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France. 2020. [2020 May 25]. Available from: https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Abstract_Raoult_EarlyTrtCovid19_09042020_vD1v.pdf.
   Google Scholar
• Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol. 2011;7(9):1153–1167.
   PubMed Web of Science ®Google Scholar